About
Our current Series A target is €10M. To date, €8.5M are already secured from the European Investment Bank (€5M), Seventure (€2.5M), and SPRIM (€0.75M to €1M).
The proceeds from this Series A round will fund our pharmaceutical development in collaboration with our CDMO partner, and enable our First-in-Human trial. This study aims to evaluate the safety and efficacy of our durg candidate in combination with an immune checkpoint inhibitor, such as pembrolizumab, in patients with relapsed/refractory advanced or metastatic TNBC.
We are eager to finalize this Series A and move forward to the clinic as soon as possible!
Organisation
Similar opportunities
Investment
High Valuation Deal: A €1M SAFE/convertible with a €10M cap converts to 10% equity
- Others
- Startup
- Possible exit
Dima Arvo
CEO/CTO/CPO at ARVO OY
Espoo, Finland
Investment
- Others
- Startup
- Growth and Establishment
- Climate & Environmental Tech
- Advanced Manufacturing & Advanced Materials
Christophe Berlo
CFO at Resortecs / regeneration BV
Brussels, Belgium
Investment
- Energy
- Expansion
- AI, Data & ICT
- Speed and Development
- Growth and Establishment
- Climate & Environmental Tech
- Quantum, Advanced Computing & Semiconductors
Lovisa Urheim
Head of Strategic Initiatives at Plexigrid
Stockholm, Sweden